MedTrace Logo

Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

NCT02655770 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI. Secondary if the treatment has any effect on the perfusion of the heart on a cardiac-MRI.

Conditions

  • Diabetes Mellitus Type 2
  • Diastolic Dysfunction
  • Cardiac MRI
  • Myocardial Perfusion

Interventions

DRUG

Liraglutide

DRUG

Placebo

Sponsors & Collaborators

  • Slagelse Hospital

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Niels Vejlstrup, MD, Med.Sc.D · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Denmark

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655770 on ClinicalTrials.gov